Reporting the NAFT major bleeding rates in context: Reviewers should include site investigator-classified rates [1] (multiple letters)

Archives of Internal Medicine

Volumn 163, Issue 3, 2003, Pages 369-

  Hull, Russell D ^a   Mah, Andrew F ^a   Calgary, ^a   Alberta, ^a   Strebel, Niklaus ^a   Prins, Martin H ^a   Büller, Harry R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TOTAL HIP PROSTHESIS;

ANTICOAGULANTS; DALTEPARIN; DOUBLE-BLIND METHOD; HEMORRHAGE; HUMANS; NORTH AMERICA; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 0037429078     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.3.369-a     Document Type: Letter

References (0)